TrialArthritis research & therapy2024

Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis.

Dafna D Gladman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.